Article in International journal of molecular sciences, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 43% of its field
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
3 · Its place in the literature
Who cites it
1 citing paper in PubMed, 2 citations in OpenAlex.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
16 authors at 6 institutions in 2 countries.
Dennis Cerrato-IzaguirreDepartamento de Farmacología, Centro de Investigación y de Estudios Avanzados del I.P.N. (CINVESTAV), Avenida Instituto Politécnico Nacional No. 2508, Ciudad de México CP. 07360, Mexico.
Yolanda I ChirinoUnidad de Biomedicina, Facultad de Estudios Superiores Iztacala, Universidad Nacional Autónoma de México, Los Reyes Iztacala, Tlalnepantla de Baz, Estado de México CP. 54090, Mexico.ORCID 0000-0001-6627-3392
Diddier PradaSubdirección de Investigación Básica, Instituto Nacional de Cancerología (INCan), San Fernando No. 22, Tlalpan, Ciudad de México CP. 14080, Mexico.ORCID 0000-0002-6517-156X
Ericka Marel Quezada-MaldonadoSubdirección de Investigación Básica, Instituto Nacional de Cancerología (INCan), San Fernando No. 22, Tlalpan, Ciudad de México CP. 14080, Mexico.ORCID 0000-0001-9895-8302
Luis A HerreraInstituto Nacional de Medicina Genómica (INMEGEN), Periférico Sur No. 4809, Arenal Tepepan, Tlalpan, Ciudad de México CP. 14610, Mexico.ORCID 0000-0003-3998-9306
Angélica Hernández-GuerreroServicio de Endoscopía, Instituto Nacional de Cancerología (INCan), San Fernando No. 22, Tlalpan, Ciudad de México CP. 14080, Mexico.
Juan Octavio Alonso-LarragaServicio de Endoscopía, Instituto Nacional de Cancerología (INCan), San Fernando No. 22, Tlalpan, Ciudad de México CP. 14080, Mexico.
Roberto Herrera-GoepfertDepartamento de Patología, Instituto Nacional de Cancerología (INCan), San Fernando No. 22, Tlalpan, Ciudad de México CP. 14080, Mexico.ORCID 0000-0001-7901-2378
Luis F Oñate-OcañaSubdirección de Investigación Clínica, Instituto Nacional de Cancerología (INCan), San Fernando No. 22, Tlalpan, Ciudad de México CP. 14080, Mexico.ORCID 0000-0002-2020-0283
David Cantú-de-LeónDirección de Investigación, Instituto Nacional de Cancerología (INCan), San Fernando No. 22, Tlalpan, Ciudad de México CP. 14080, Mexico.ORCID 0000-0002-6693-8347
Abelardo Meneses-GarcíaDirección General, Instituto Nacional de Cancerología (INCan), San Fernando No. 22, Tlalpan, Ciudad de México CP. 14080, Mexico.
Patricia Basurto-LozadaLaboratorio Internacional de Investigación Sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro CP. 76010, Mexico.
Carla Daniela Robles-EspinozaLaboratorio Internacional de Investigación Sobre el Genoma Humano, Universidad Nacional Autónoma de México, Santiago de Querétaro CP. 76010, Mexico.
Javier CamachoDepartamento de Farmacología, Centro de Investigación y de Estudios Avanzados del I.P.N. (CINVESTAV), Avenida Instituto Politécnico Nacional No. 2508, Ciudad de México CP. 07360, Mexico.ORCID 0000-0002-8886-086X
Claudia M García-CuellarSubdirección de Investigación Básica, Instituto Nacional de Cancerología (INCan), San Fernando No. 22, Tlalpan, Ciudad de México CP. 14080, Mexico.ORCID 0000-0001-8080-5797
Yesennia Sánchez-PérezSubdirección de Investigación Básica, Instituto Nacional de Cancerología (INCan), San Fernando No. 22, Tlalpan, Ciudad de México CP. 14080, Mexico.ORCID 0000-0003-0103-9188
Instituto Nacional de Cancerología · MXAutonomous University of Tlaxcala · MXInstituto Politécnico Nacional · MXNational Institute of Genomic Medicine · MXUniversidad Nacional Autónoma de México · MXWellcome Sanger Institute · GB
Funding
Early Exposure to Persistent Organic Pollutants, Breast Milk Extracellular Vesicles and Abnormal Cardiometabolic ProgrammingR21ES027087 · NIEHS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI BACCARELLI, ANDREA, PRADA, DIDDIER GIOVANNI · 2016 to 2017
$438k
NIEHS NIH HHS R21 ES027087
6 · The paper itself
Abstract
The Hispanic population, compared with other ethnic groups, presents a more aggressive gastric cancer phenotype with higher frequency of diffuse-type gastric adenocarcinoma (GA); this could be related to the mutational landscape of GA in these patients. Using whole-exome sequencing, we sought to present the mutational landscape of GA from 50 Mexican patients who were treated at The Instituto Nacional de Cancerología from 2019 to 2020. We performed a comprehensive statistical analysis to explore the relationship of the genomic variants and clinical data such as tumor histology and presence of signet-ring cell,
Indexed as
AdenocarcinomaHelicobacter pyloriStomach NeoplasmsAntigens, CDCadherinsExome SequencingHumansMutationAntigens, CDCadherinsCDH1 protein, humancancer genomicscopy number variationgastric cancerHispanic ethnicitymutationsprecision medicine
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Somatic Mutational Landscape in Mexican Patients: · full record | OpenQuestion